NCT02998905View on ClinicalTrials.gov

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

February 18, 2020

Conditions
Atrial FibrillationIntracerebral Hemorrhage
Interventions
DRUG

NOAC

Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.

DRUG

Acetylsalicylic Acid

Acetylsalicylic acid 81 mg/day

Trial Locations (9)

T2N 4N1

Foothills Medical Centre, Calgary

Unknown

University of Alberta Hospital, Edmonton

London Health Sciences Centre - University Hospital, London

The Ottawa Hospital Research Institute, Ottawa

Sunnybrook Health Sciences Centre, Toronto

Toronto Western Hospital, Toronto

Hopital Notre-Dame du CHUM, Montreal

V6T 2B5

Vancouver Coastal Health Research Institute, Vancouver

L9G1J8

Hamilton Health Sciences, Hamilton

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER